SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 1, 2026 - P3 | N=577 | Terminated | Sponsor: Mirati Therapeutics Inc. | Completed ➔ Terminated; Inability to meet protocol objectives
Checkpoint inhibition • Trial termination • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1
|